Skip to main content

Nu-Med Plus Presents at the 147th National Investment Banking Association Conference on November 12-13, 2019 in New York City

Written by Customer Service on . Posted in Public Companies.

SALT LAKE CITY, Dec. 03, 2019 (GLOBE NEWSWIRE) — Nu-Med Plus, Inc. (OTCQB: NUMD), announced today that the Company attended and presented at the 147th National Investment Banking Association (NIBA) conference scheduled for November 12-13, 2019 at the Westin Times Square Hotel in New York City.
The opportunity to present the Nu-Med Plus story to both the investment community and those interested in potential collaboration using our Core Nitric Oxide Delivery technology looks to be a great success. There were many investment bankers and brokerage professionals in the audience at this event, which immediately translated into a full schedule of follow up meetings for Nu-Med Plus Management. Furthermore, Nu-Med Plus already is scheduling follow up conference calls and additional meetings and presentations through the rest of December and January 2020. “The positive response from our presentation at the NIBA Conference has been amazing,” commented Jeff Robins, President and CEO of NU-Med Plus. About Nu-Med Plus, Inc.
Nu-Med Plus, Inc. (OTCMARKETS: NUMD) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices. Nu-Med Plus, Inc. was created to develop new nitric oxide delivery technology and focus applications on high growth-potential markets where a clearly defined need has been recognized by the medical community. Nu-Med Plus aggressively pursues research and development into innovative nitric oxide delivery. The company holds one patent and currently has three patents pending related to Nu-Med Plus precision nitric oxide delivery. Our breakthroughs demonstrate the possibility of increased efficacy, lower costs, and increased portability. This intellectual property portfolio cements a strong foundation for additional patents, creates value for shareholders and safeguards against encroachment by future competition.Nu-Med Plus develops industry redefining products that are portable, cost less, operate more efficiently, and offer user-friendly designs. These advancements hold the potential to break down barriers and open new markets which are often inaccessible due to the current prohibitive price and immobility of traditional nitric oxide delivery systems.  Nu-Med Plus and its core Delivery Technology have been anticipating the conclusive phase of their nitric oxide delivery device for use in the neonatal intensive care unit (NICU). The time has arrived for the upcoming Food and Drug Administration (FDA) submission for the 510(k)-approval process. Which should be Q2 2020.About National Investment Banking Association (NIBA)
Since 1982, the National Investment Banking Association (NIBA) has been serving the micro-cap and small-cap investment community. We have hosted 146 investment conferences showcasing hundreds of public and private companies seeking access to the financial industry. Our network has raised over $17 billion and is responsible for 90% of all IPOs under $20 million. Our network is made up of thousands of investment professionals representing over 60 key industry services and includes over 8,800 registered representatives that have over $78 billion in assets under management.Additional details about the National Investment Banking Association’s 147th Investment Conference, Nov. 12-13, 2019, in New York City can be found at: https://nibanet.org/conferences/niba-november-12-13-2019-new-york-ny-conference.   Contact:
Jeff Robins
Email: Jeff@nu-medplus.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.